TriClip™ - Patients who benefit

TRICLIP™
TRICUSPID
VALVE REPAIR
TRANSCATHETER
EDGE-TO-EDGE REPAIR (TEER)

TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive
treatment option for patients with symptomatic, severe tricuspid regurgitation (TR)
who are at high risk for surgery.¹

A STATE-OF-THE-ART TREATMENT OPTION FOR PATIENTS AT HIGH RISK FOR SURGERY

TriClip™ TEER is a low risk,⁵ minimally invasive, non-surgical treatment option for symptomatic patients with severe Tricuspid Regurgitation (TR) who are at high risk for surgery and are not seeing improvement from medical therapy alone.

TriClip™ Patient Story: Cruz

TriClip™ Patient Story: Narcisa

TriClip™ Patient Story: Javier

Transcatheter beating heart procedure - no cardiopulmonary bypass
Allows for real-time positioning and repositioning to optimize TR reduction
Femoral venous access

Can be used in a standard cath lab or hybrid room
No pre-procedural CT required
Fast recovery times; many patients go home the next day⁴

Patients with severe tricuspid regurgitation have significantly impaired quality of life¹²

Shortness of breath
Peripheral edema
Ascites
Fatigue
Declining exercise capacity

Current treatment options have limitations

For many patients with Functional Tricuspid Regurgitation (FTR), medical management is not enough.

MEDICAL MANAGEMENT FOR TR HAS LITTLE IMPACT ON SURVIAL⁶

66%

of patients with severe FTR die within 5 years of medical management⁶

Most patients receive medical management until right heart failure or end-organ dysfunction appears.⁷

Surgery is high risk and often denied^8,9

Surgery for TR is seldom performed. Factors prohibiting surgery include:

High operative risk (6–16% in-hospital mortality)
Multiple comorbidities
Advanced age
Lack of effectiveness

LONG-TERM SURVIVAL ESTIMATES FOR ALL PATIENTS UNDERGOING SURGICAL TRICUSPID VALVE REPLACEMENT OR REPAIR¹⁰

Connext
Hub

Learn emerging and established information on cardiovascular conditions and stroke prevention technologies.

Find out more

TV

T-TEER: Transcatheter Tricuspid Valve Repair - cases, tips, and tricks

T-TEER: echo procedural approach

T-TEER: echo procedural approach for Transcatheter Tricuspid Repair

T-TEER: patient selection and current evidence

T-TEER: patient selection and current evidence for TR Repair

Anatomical overview of the AV Valves

Anatomical overview of the AV Valves and structures

Screening Transmission | Mitral focus

Screening Transmission | Mitral focus

F. Maisano, M. Swaans, M. Adam. M. Weber

TriClip - AVVS 1 year 1 minute Tricuspid - Video

The most significant moments of the past year | Tricuspid focus

MitraClip - AVVS 1 year 1 minute Mitral - Video

The most significant moments of the past year | Mitral focus

AV Valves Summit 2024 | Closing of Day 2

AV Valves Summit 2024 | Closing of Day 2

F. Maisano, M. Metra, M. Sitges, R. S. Von Bardeleben

Trending Controversies | AV Valves

Trending Controversies | AV Valves

R. S. Von Bardeleben, M. Sitges, D. Tchetche, M. Swaans, M. Taramasso, C. Trani, K. Gatenby, M. Adamo, M. Barreiro, A. Linke, V. Ninios, J. Odenstedt, S. Berti, N. Ajmone Marsan

Case Parade | Mitral focus

Case Parade | Mitral focus

M. Sitges, V. Ninios, J. Van der Heyden, K. Gatenby, D. Arzamendi, M. Shuvy, M. Adam

References

TriClip G4 System IFU.
Tests(s) performed and data on file at Abbott (RPT2118537)
Estevez-Loureiro R. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 2-year Outcomes from the bRIGHT Trial. Presented at PCR London Valves on November 19-21, 2023; London, UK.
Adams D, Sorajja P, et al. TRILUMINATE Pivotal: Outcomes of All Randomized and Single-arm Subjects with Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation. Presented at TCT on October 24,2023; San Francisco, CA; USA.
Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. NEJM. March 4, 2023. doi: 10.1056/NEJMoa2300525.
Benfari G, Antoine C, Mille WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. 2019;140(3):196-206.
Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol. 2018;71(25):2935-2956.
Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, et al. Tricuspid regurgitation is a public health crisis [published online ahead of print November 9, 2019]. Prog Cardiovasc Dis. 2019;62(6):447-451. Doi:10.1016/j.pcad.2019.10.009.
Wong WK, Chen SW, Chou AH, et al. Late outcomes of valve repair versus replacement in isolated and concomitant tricuspid valve surgery: a nationwide cohort study. J Am Heart Assoc. 2020;9(8):e015637. doi:10.1161/JAHA.119.015637.
Moraca RJ, Moon MR, Lawton JS, Guthrie TJ, Aubuchon KA, Moazami N, Pasque MK, Damiano RJ Jr. Outcomes of tricuspid valve repair and replacement: a propensity analysis. Ann Thorac Surg. 2009 Jan;87(1):83-8; discussion 88-9.
Test(s) performed by and data on file at Abbott. (RPT2133700, RPT2122822-R, RPT2124838-R)
www.mayoclinic.org. Assessed February 2024.
Data on File at Abbott.
Test(s) performed by and data on file at Abbott. (RPT2105461-R)
Test(s) performed by and data on file at Abbott. (RPT2124196-R)